26 July 2023
26 July 2023
The two companies have expanded their collaboration agreement, making Teva more involved in manufacturing and adding further biosimilars to the deal.
The tender offer is now updated to expire on 8 August 2023.
Partnerships, mergers, business combinations, and acquisitions could all be on the horizon for the biotech.
This approval comes backed by data from the ICONIC study, which includes six years of data across the LIVMARLI clinical programme.
The approval was based on data from the EMPA-KIDNEY study, which demonstrated a significant benefit of empagliflozin in treating CKD.
Astellas will also make milestone payments totalling up to $145m per target to PeptiDream.
The funding will help the company advance its cell therapy clinical trials intended to treat blood and immune diseases.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
